Breakthrough Mitochondrial Science A Source for Novel Therapeutics

CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on developing therapeutic peptides derived from the mitochondrial genome.

Q3 Investor Conference Call – Audio Replay

AASLD 2021 Poster

Corporate Presentation

Harnessing the Therapeutic Potential of Mitochondrial DNA

Our company is a leader in exploring the mitochondrial genome for therapeutically relevant peptides, focusing on those peptides that have important roles in systemic pathways. We believe that many of these peptides have been conserved by evolutionary biology due to their important roles in sensing and regulating critical biological functions, far beyond the energy production most frequently associated with mitochondria. Our team has discovered more than 100 mitochondrial derived peptides (MDPs) and generated over 1,000 analogs.

Our Science

Proprietary Platform Technology

CohBar has developed a proprietary platform technology, using cell-based assays and animal models of disease, to rapidly identify naturally occurring MDPs with promising biological activity. Once identified, we deploy optimization techniques to improve the drug-like properties of our MBT candidates, enabling us to match the most biologically promising peptides to disease indications that have substantial unmet medical needs. Our ongoing research and development activities focus on discovery and development of novel improved MDP analogs that have the greatest therapeutic and commercial potential. Recent data continues to strengthen the evidence supporting the breadth of biological effects and therapeutic potential of our novel analogs of mitochondrial peptides.

Our Platform

Pipeline of Clinical and Preclinical Programs

The company’s lead compound, CB4211, which is under development for the treatment of nonalcoholic steatohepatitis (NASH) and obesity, demonstrated positive effects in reducing biomarkers of liver injury and glucose levels in a successful Phase 1a/1b clinical trial in August 2021. In addition, CohBar has selected CB5138-3 as its second clinical candidate, a peptide with broad anti-fibrotic and anti-inflammatory properties in disease models.  This program is currently in the IND-enabling stage and we expect to file an IND and initiate a First-in-Human study in 2022, with an initial indication of idiopathic pulmonary fibrosis (IPF). The company also has a program in acute respiratory distress syndrome (ARDS), including COVID-19 associated ARDS, as well as two peptide families in early discovery with potential utility in treating various forms of cancer.

Our Pipeline

Stock Information

CohBar, Inc.


Nasdaq: CWBR




Day Range

52 Week Range

Email Sign Up